N-[3-(1,3-benzothiazol-2-yl)-6-benzyl-5,7-dihydro-4H-thieno[2,3-c]pyridin-2-yl]-2,2-dimethylpropanamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 英文名称: N-[3-(1,3-benzothiazol-2-yl)-6-benzyl-5,7-dihydro-4H-thieno[2,3-c]pyridin-2-yl]-2,2-dimethylpropanamide
• 化学式: C₂₆H₂₇N₃OS₂
• 分子量: 461.6
• InChiKey: IZHKZGGOHNYVLL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  32
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  102
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• BENZOTHIAZOLYL THIENOPYRIDINE DERIVATIVES AND USES THEREOF
  申请人：Gregor Paul

  公开号：US20100298370A1

  公开（公告）日：2010-11-25

  Novel benzothiazolyl thienopyridine compounds are provided and pharmaceutical compositions comprising benzothiazolyl thienopyridine compounds. The benzothiazolyl thienopyridine compounds are capable of inhibiting the interactions between vascular endothelial growth factor (VEGF) and heparan sulfate glycosaminoglycans (HS-GAGs), and are useful for prevention or treatment of diseases and disorders such as inflammation, autoimmune diseases and cancer.

  提供了新型苯并噻唑基噻吡啶化合物以及含有苯并噻唑基噻吡啶化合物的药物组合物。这些苯并噻唑基噻吡啶化合物能够抑制血管内皮生长因子（VEGF）与肝素硫酸甘露聚糖（HS-GAGs）之间的相互作用，可用于预防或治疗炎症、自身免疫疾病和癌症等疾病和疾病。
• [EN] BENZOTHIAZOLYL THIENOPYRIDINE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE THIÉNOPYRIDINE DE TYPE BENZOTHIAZOLYLE ET LEURS APPLICATIONS
  申请人：RIMONYX PHARMACEUTICALS LTD

  公开号：WO2008020438A2

  公开（公告）日：2008-02-21

  [EN] Novel benzothiazolyl thienopyridine compounds are provided and pharmaceutical compositions comprising benzothiazolyl thienopyridine compounds. The benzothiazolyl thienopyridine compounds are capable of inhibiting the interactions between vascular endothelial growth factor (VEGF) and heparan sulfate glycosaminoglycans (HS-GAGs), and are useful for prevention or treatment of diseases and disorders such as inflammation, autoimmune diseases and cancer.
  [FR] La présente invention concerne de nouvelles benzothiazolylthiénopyridines ainsi que les compositions pharmaceutiques comprenant lesdites benzothiazolylthiénopyridines. Les benzothiazolylthiénopyridines sont susceptibles d'inhiber les interactions entre le facteur de croissance endothéliale vasculaire (VEGF) et les glycosaminoglycanes de type héparane-sulfate (HS-GAG), et peuvent être employées dans le traitement prophylactique ou thérapeutique de maladies et de troubles tels que l'inflammation, les maladies auto-immunes et les cancers.